Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group
Background Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2022-04, Vol.115 (4), p.515-524 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 524 |
|---|---|
| container_issue | 4 |
| container_start_page | 515 |
| container_title | International journal of hematology |
| container_volume | 115 |
| creator | Kitamura, Wataru Fujii, Nobuharu Nawa, Yuichiro Fujishita, Keigo Sugiura, Hiroyuki Yoshioka, Takanori Fujiwara, Yuki Usui, Yoshiaki Fujii, Keiko Fujiwara, Hideaki Asada, Noboru Nishimori, Hisakazu Matsuoka, Ken-ichi Maeda, Yoshinobu |
| description | Background
Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group).
Methods
We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo.
Results
The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (
p
|
| doi_str_mv | 10.1007/s12185-022-03290-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626009269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626009269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-d80e319649276308990ed6cd7a487fcf0808d5f6797414818959e4d5ca0492413</originalsourceid><addsrcrecordid>eNp9ksFu1TAQRQMC0UfhB1igkdhUQgE7TuK4u6qCFqmiCIpYRn6J85Jix8Z2RLNjy2_yJUxeCpVYsLBsyefeGY9vkjyj5BUlhL8ONKNVkZIsSwnLBEnZ_WRDq7JIGef5g2RDRFakBafkIHkcwjUhlJOcP0oOWEGpKAu6ubf5YEMYtlqB83Y32hCHBgbjZBPBdvDlioL5-P4E1I3zCkk7gozQyvnXj58vcTECsovKQy-dtkOrRjSQGpzyg-uVx-NWW9tCiMpAo7SG6OUYnJZjlHHx-z7EHhxWvruAZm60db0NrpcGXaGzHhzy6B9WhZnVUhBGZVETzDFIMJPG8shgQyFO7QydtwZir-Dyq5ylkXCujIxW292-zU976MzbyT1JHnZSB_X0dj9MPr99c3V6nl5cnr07PblIGyZETNuKKIbDy0XGS0YqIYhqy6blMq9413SkIlVbdCUXPKd5RStRCJW3RSMJSnLKDpOj1RcH_m1SIdZmCMtgJL5kCnVWZiXBnysFoi_-Qa_t5EfsDqm8YLQs6WKYrVTj8S-96mrnByP9XFNSL0Gp16DUGJR6H5Saoej5rfW0Nar9K_mTDATYCgS8GnfK39X-j-1vw7LP5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645316611</pqid></control><display><type>article</type><title>Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kitamura, Wataru ; Fujii, Nobuharu ; Nawa, Yuichiro ; Fujishita, Keigo ; Sugiura, Hiroyuki ; Yoshioka, Takanori ; Fujiwara, Yuki ; Usui, Yoshiaki ; Fujii, Keiko ; Fujiwara, Hideaki ; Asada, Noboru ; Nishimori, Hisakazu ; Matsuoka, Ken-ichi ; Maeda, Yoshinobu</creator><creatorcontrib>Kitamura, Wataru ; Fujii, Nobuharu ; Nawa, Yuichiro ; Fujishita, Keigo ; Sugiura, Hiroyuki ; Yoshioka, Takanori ; Fujiwara, Yuki ; Usui, Yoshiaki ; Fujii, Keiko ; Fujiwara, Hideaki ; Asada, Noboru ; Nishimori, Hisakazu ; Matsuoka, Ken-ichi ; Maeda, Yoshinobu</creatorcontrib><description>Background
Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group).
Methods
We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo.
Results
The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (
p
< 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (
p
= 0.03).
Conclusions
The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-022-03290-3</identifier><identifier>PMID: 35119651</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antigens ; Cyclophosphamide ; Cyclophosphamide - therapeutic use ; Gene expression ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - etiology ; Graft vs Host Disease - prevention & control ; Graft-versus-host reaction ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; Humans ; Leukocytes ; Medical prognosis ; Medicine ; Medicine & Public Health ; Neoplasms ; Neoplasms - drug therapy ; Oncology ; Original Article ; Patients ; Peripheral blood ; Peripheral Blood Stem Cell Transplantation ; Prognosis ; Prophylaxis ; Retrospective Studies ; RNA, Messenger - genetics ; Stem cell transplantation ; Stem cells ; Transplantation ; Tumors ; WT1 Proteins - genetics</subject><ispartof>International journal of hematology, 2022-04, Vol.115 (4), p.515-524</ispartof><rights>Japanese Society of Hematology 2022</rights><rights>2022. Japanese Society of Hematology.</rights><rights>Japanese Society of Hematology 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-d80e319649276308990ed6cd7a487fcf0808d5f6797414818959e4d5ca0492413</citedby><cites>FETCH-LOGICAL-c399t-d80e319649276308990ed6cd7a487fcf0808d5f6797414818959e4d5ca0492413</cites><orcidid>0000-0002-8043-7768</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-022-03290-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-022-03290-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35119651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kitamura, Wataru</creatorcontrib><creatorcontrib>Fujii, Nobuharu</creatorcontrib><creatorcontrib>Nawa, Yuichiro</creatorcontrib><creatorcontrib>Fujishita, Keigo</creatorcontrib><creatorcontrib>Sugiura, Hiroyuki</creatorcontrib><creatorcontrib>Yoshioka, Takanori</creatorcontrib><creatorcontrib>Fujiwara, Yuki</creatorcontrib><creatorcontrib>Usui, Yoshiaki</creatorcontrib><creatorcontrib>Fujii, Keiko</creatorcontrib><creatorcontrib>Fujiwara, Hideaki</creatorcontrib><creatorcontrib>Asada, Noboru</creatorcontrib><creatorcontrib>Nishimori, Hisakazu</creatorcontrib><creatorcontrib>Matsuoka, Ken-ichi</creatorcontrib><creatorcontrib>Maeda, Yoshinobu</creatorcontrib><title>Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Background
Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group).
Methods
We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo.
Results
The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (
p
< 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (
p
= 0.03).
Conclusions
The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.</description><subject>Antigens</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Gene expression</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Graft-versus-host reaction</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Leukocytes</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Peripheral Blood Stem Cell Transplantation</subject><subject>Prognosis</subject><subject>Prophylaxis</subject><subject>Retrospective Studies</subject><subject>RNA, Messenger - genetics</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation</subject><subject>Tumors</subject><subject>WT1 Proteins - genetics</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ksFu1TAQRQMC0UfhB1igkdhUQgE7TuK4u6qCFqmiCIpYRn6J85Jix8Z2RLNjy2_yJUxeCpVYsLBsyefeGY9vkjyj5BUlhL8ONKNVkZIsSwnLBEnZ_WRDq7JIGef5g2RDRFakBafkIHkcwjUhlJOcP0oOWEGpKAu6ubf5YEMYtlqB83Y32hCHBgbjZBPBdvDlioL5-P4E1I3zCkk7gozQyvnXj58vcTECsovKQy-dtkOrRjSQGpzyg-uVx-NWW9tCiMpAo7SG6OUYnJZjlHHx-z7EHhxWvruAZm60db0NrpcGXaGzHhzy6B9WhZnVUhBGZVETzDFIMJPG8shgQyFO7QydtwZir-Dyq5ylkXCujIxW292-zU976MzbyT1JHnZSB_X0dj9MPr99c3V6nl5cnr07PblIGyZETNuKKIbDy0XGS0YqIYhqy6blMq9413SkIlVbdCUXPKd5RStRCJW3RSMJSnLKDpOj1RcH_m1SIdZmCMtgJL5kCnVWZiXBnysFoi_-Qa_t5EfsDqm8YLQs6WKYrVTj8S-96mrnByP9XFNSL0Gp16DUGJR6H5Saoej5rfW0Nar9K_mTDATYCgS8GnfK39X-j-1vw7LP5g</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Kitamura, Wataru</creator><creator>Fujii, Nobuharu</creator><creator>Nawa, Yuichiro</creator><creator>Fujishita, Keigo</creator><creator>Sugiura, Hiroyuki</creator><creator>Yoshioka, Takanori</creator><creator>Fujiwara, Yuki</creator><creator>Usui, Yoshiaki</creator><creator>Fujii, Keiko</creator><creator>Fujiwara, Hideaki</creator><creator>Asada, Noboru</creator><creator>Nishimori, Hisakazu</creator><creator>Matsuoka, Ken-ichi</creator><creator>Maeda, Yoshinobu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8043-7768</orcidid></search><sort><creationdate>20220401</creationdate><title>Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group</title><author>Kitamura, Wataru ; Fujii, Nobuharu ; Nawa, Yuichiro ; Fujishita, Keigo ; Sugiura, Hiroyuki ; Yoshioka, Takanori ; Fujiwara, Yuki ; Usui, Yoshiaki ; Fujii, Keiko ; Fujiwara, Hideaki ; Asada, Noboru ; Nishimori, Hisakazu ; Matsuoka, Ken-ichi ; Maeda, Yoshinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-d80e319649276308990ed6cd7a487fcf0808d5f6797414818959e4d5ca0492413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Gene expression</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Graft-versus-host reaction</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Leukocytes</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Peripheral Blood Stem Cell Transplantation</topic><topic>Prognosis</topic><topic>Prophylaxis</topic><topic>Retrospective Studies</topic><topic>RNA, Messenger - genetics</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation</topic><topic>Tumors</topic><topic>WT1 Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitamura, Wataru</creatorcontrib><creatorcontrib>Fujii, Nobuharu</creatorcontrib><creatorcontrib>Nawa, Yuichiro</creatorcontrib><creatorcontrib>Fujishita, Keigo</creatorcontrib><creatorcontrib>Sugiura, Hiroyuki</creatorcontrib><creatorcontrib>Yoshioka, Takanori</creatorcontrib><creatorcontrib>Fujiwara, Yuki</creatorcontrib><creatorcontrib>Usui, Yoshiaki</creatorcontrib><creatorcontrib>Fujii, Keiko</creatorcontrib><creatorcontrib>Fujiwara, Hideaki</creatorcontrib><creatorcontrib>Asada, Noboru</creatorcontrib><creatorcontrib>Nishimori, Hisakazu</creatorcontrib><creatorcontrib>Matsuoka, Ken-ichi</creatorcontrib><creatorcontrib>Maeda, Yoshinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitamura, Wataru</au><au>Fujii, Nobuharu</au><au>Nawa, Yuichiro</au><au>Fujishita, Keigo</au><au>Sugiura, Hiroyuki</au><au>Yoshioka, Takanori</au><au>Fujiwara, Yuki</au><au>Usui, Yoshiaki</au><au>Fujii, Keiko</au><au>Fujiwara, Hideaki</au><au>Asada, Noboru</au><au>Nishimori, Hisakazu</au><au>Matsuoka, Ken-ichi</au><au>Maeda, Yoshinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>115</volume><issue>4</issue><spage>515</spage><epage>524</epage><pages>515-524</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Background
Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms’ tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group).
Methods
We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo.
Results
The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (
p
< 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (
p
= 0.03).
Conclusions
The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>35119651</pmid><doi>10.1007/s12185-022-03290-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8043-7768</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2022-04, Vol.115 (4), p.515-524 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2626009269 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antigens Cyclophosphamide Cyclophosphamide - therapeutic use Gene expression Graft vs Host Disease - drug therapy Graft vs Host Disease - etiology Graft vs Host Disease - prevention & control Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Histocompatibility antigen HLA Humans Leukocytes Medical prognosis Medicine Medicine & Public Health Neoplasms Neoplasms - drug therapy Oncology Original Article Patients Peripheral blood Peripheral Blood Stem Cell Transplantation Prognosis Prophylaxis Retrospective Studies RNA, Messenger - genetics Stem cell transplantation Stem cells Transplantation Tumors WT1 Proteins - genetics |
| title | Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A24%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20prognostic%20impact%20of%20WT1%20mRNA%20expression%20at%20day%E2%80%89+%E2%80%8930%20after%20haploidentical%20peripheral%20blood%20stem%20cell%20transplantation%20with%20posttransplant%20cyclophosphamide%20for%20patients%20with%20myeloid%20neoplasm:%20a%20multicenter%20study%20from%20the%20Okayama%20Hematological%20Study%20Group&rft.jtitle=International%20journal%20of%20hematology&rft.au=Kitamura,%20Wataru&rft.date=2022-04-01&rft.volume=115&rft.issue=4&rft.spage=515&rft.epage=524&rft.pages=515-524&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-022-03290-3&rft_dat=%3Cproquest_cross%3E2626009269%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645316611&rft_id=info:pmid/35119651&rfr_iscdi=true |